Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation?
Matrilysin or MMP-7, one of the smallest of all known matrix metalloproteinases (MMPs), has been studied extensively in many different tumor types, since its discovery more than 20 years ago. However, research during the past several years has revealed that this protease also plays an essential role in innate immunity, and, more particularly, in inflammatory disorders.
Wielockx
Ben
B
Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology, Ghent University, Ghent (Zwijnaarde), Belgium.
Libert
Claude
C
Wilson
Carole
C
D000818:Animals; D015195:Drug Design; D004847:Epithelial Cells / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000201:enzymology* / Q000209:etiology; D008168:Lung / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D020783:Matrix Metalloproteinase 7 / Q000276:immunology / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D009369:Neoplasms / Q000201:enzymology* / Q000209:etiology; D014945:Wound Healing / Q000276:immunology / Q000502:physiology
D061965:Matrix Metalloproteinase Inhibitors; D020783:Matrix Metalloproteinase 7